These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1880231)

  • 1. Pharmacokinetics of ceftriaxone in liver-transplant recipients.
    Toth A; Abdallah HY; Venkataramanan R; Teperman L; Halsf G; Rabinovitch M; Burckart GJ; Starzl TE
    J Clin Pharmacol; 1991 Aug; 31(8):722-8. PubMed ID: 1880231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.
    McNamara PJ; Stoeckel K; Ziegler WH
    Eur J Clin Pharmacol; 1982; 22(1):71-5. PubMed ID: 6284519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
    Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
    Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose ceftriaxone kinetics in the newborn.
    Schaad UB; Hayton WL; Stoeckel K
    Clin Pharmacol Ther; 1985 May; 37(5):522-8. PubMed ID: 3987175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.
    Simon N; Dussol B; Sampol E; Purgus R; Brunet P; Lacarelle B; Berland Y; Bruguerolle B; Urien S
    Clin Pharmacokinet; 2006; 45(5):493-501. PubMed ID: 16640454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.
    McNamara PJ; Gibaldi M; Stoeckel K
    Eur J Clin Pharmacol; 1983; 25(3):399-405. PubMed ID: 6313379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
    Albin H; Ragnaud JM; Demotes-Mainard F; Vinçon G; Couzineau M; Wone C
    Eur J Clin Pharmacol; 1986; 31(4):479-83. PubMed ID: 3816928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma protein binding of ceftriaxone.
    Popick AC; Crouthamel WG; Bekersky I
    Xenobiotica; 1987 Oct; 17(10):1139-45. PubMed ID: 3424863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition kinetics and dosage regimen of ceftriaxone in crossbred calves (short communication).
    Johal B; Srivastava AK
    Acta Vet Hung; 1999; 47(2):243-8. PubMed ID: 10344084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and dosage regimen of ceftriaxone in buffalo calves.
    Dardi MS; Sharma SK; Srivastava AK
    Vet Res Commun; 2004 May; 28(4):331-8. PubMed ID: 15222737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ceftriaxone in patients with typhoid fever.
    Acharya G; Crevoisier C; Butler T; Ho M; Tiwari M; Stoeckel K; Bradley CA
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2415-8. PubMed ID: 7840580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of ceftriaxone in the first three month of life].
    Rondanelli R; Regazzi MB; Stronati M; Calvi M; Lombardi G; Rondini G
    Pediatr Med Chir; 1992; 14(1):55-9. PubMed ID: 1579518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man.
    Maudgal DP; Maxwell JD; Lees LJ; Wild RN
    Br J Clin Pharmacol; 1982 Aug; 14(2):213-7. PubMed ID: 6285946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
    Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
    J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftriaxone disposition in open-heart surgery patients.
    Jungbluth GL; Pasko MT; Beam TR; Jusko WJ
    Antimicrob Agents Chemother; 1989 Jun; 33(6):850-6. PubMed ID: 2764536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
    Karim A
    J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
    Stoeckel K; Koup JR
    Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Free concentration and protein binding of ceftriaxone].
    Saionji K; Miyake N; Miyake K; Igari J; Kobayashi I; Satoh Y
    Jpn J Antibiot; 1992 Feb; 45(2):136-42. PubMed ID: 1613966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the relationship between serum and milk residue disposition of ceftriaxone in lactating ewes.
    Goudah A; Shin HC; Shim JH; Abd El-Aty AM
    J Vet Pharmacol Ther; 2006 Aug; 29(4):307-12. PubMed ID: 16846468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.